


What is claimed is:

1. A compound of the formula:

5



A

- 10 in which:

R_1 is independently selected from the group consisting of hydrogen; hydroxy; halo; C_{1-8} alkyl; substituted C_{1-8} alkyl; C_{1-8} alkoxy; substituted C_{1-8} alkoxy; trifluoroalkyl; C_{1-8} alkylthio; substituted C_{1-8} alkylthio; C_{3-6} cycloalkyl; C_{3-8} cycloalkoxy; nitro; amino; C_{1-6} alkylamino; C_{1-8} dialkylamino; C_{4-8} cycloalkylamino; cyano; carboxy; C_{1-5} alkoxycarbonyl; C_{1-5} alkylcarbonyloxy; formyl; carbamoyl; phenyl; and substituted phenyl;

- 20 n is 1-2;

B_1 is hydrogen;

- 25 B_2 is hydrogen; or B_1 and B_2 are methylene and joined together to form a five or six membered ring;


m is 0-3;

R_2 is independently selected from the group consisting of hydrogen; hydroxy; C_{1-6} alkyl; C_{2-6} alkenyl; halo; C_{3-7} cycloalkyl; phenyl; substituted phenyl; naphthyl, substituted naphthyl; phenoxy; substituted phenoxy; heteroaryl; substituted heteroaryl; and heterocycloalkyl;


5

L is selected from the group consisting of C_{1-8} alkylene; C_{2-10} alkenylene; C_{2-10} alkynylene; C_{3-7} cycloalkylene; C_{3-7} cycloalkyl C_{1-4} alkylene; aryl C_{1-4} alkylene; α -amino C_{4-7} alkylene;

10




(N-methylene)piperidin-4-yl;




15

(N-methylene)piperazin-4-yl;




20

(N-methylene)pyrrolidin-3-yl;




(N-methylene)-4-acetyl-piperidin-4-yl;



25


and (N-methylene)piperidin-4,4-diyl;




5 Y is methylene or carbonyl;

Z is selected from the group consisting of:


aryl;




N-sulfonamido;




N-(aryl)sulfonamido;




arylamido;




arylureido;



arylacetamido:




(aryloxy)carbonylamino;




5

2,3-dihydro-2-oxo-1H-benzimidazol-1-yl;



and 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;



10

R_3 is independently selected from the group consisting of C_{1-6} alkyl; substituted C_{1-8} alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl; and substituted heteroaryl;

15

R_4 is independently selected from the group consisting of hydrogen; C_{1-8} alkyl; C_{1-8} alkoxy; substituted C_{1-8} alkoxy; hydroxy; halogen; cyano; nitro; amino; C_{1-8} alkylamino; and C_{1-8} dialkylamino;

20

R_5 is independently selected from the group consisting of hydrogen;
 C_{1-8} alkyl; C_{1-8} alkylcarbonyl; aroyl; carbamoyl; amidino; C_{1-8} alkyl;
 C_{1-8} alkylaminocarbonyl; (arylamino)carbonyl; and aryl C_{1-8} alkylcarbonyl;

5 R_6 is independently selected from hydrogen and C_{1-8} alkyl;

p is 1-3;

q is 1-3;

10

and enantiomers, diastereomers and pharmaceutically acceptable salts thereof;

provided that when L is C_{1-6} alkylene; C_{2-10} alkenylene; C_{2-10} alkynylene;

15 C_{3-7} cycloalkylene; C_{3-7} cycloalkyl C_{1-4} alkylene; aryl C_{1-4} alkylene; or α -amino C_{4-7} alkylene; then Z is phenyl, N-sulfonamido or N-(aryl)sulfonamido;

when L is (N-methylene)piperazin-4-yl; then Z is phenyl or naphthyl;

20 when L is (N-methylene)pyrrolidin-3-yl or (N-methylene)piperidin-4-yl; then Z is N-sulfonamido; N-(aryl)sulfonamido; 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl; benzamido; phenylureido; phenylacetamido or (phenoxy)carbonylamino;

25 when L is (N-methylene)-4-acetyl-piperidin-4-yl; then Z is phenyl or naphthyl and Y is carbonyl;

when L is (N-methylene)piperidin-4,4-diyl; then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl and Y is carbonyl;

30 and when B_1 and B_2 are both methylene thus forming a six membered ring and when L is C_{1-10} alkylene; C_{2-10} alkenylene; C_{2-10} alkenylene; or aryl C_{1-4} alkylene; then Z is other than N-sulfonamido, N-(aryl)sulfonamido or phenyl.

2. A compound of claim 1 wherein R₁ is H; alkyl; substituted alkyl; alkoxy; halo; substituted alkoxy; hydroxy; trifluoralkyl; nitro; amino; alkylamino; cycloalkylamino; cyano; carboxy; cycloalkyl; phenyl; and substituted phenyl;

5

R₂ is H; hydroxy; alkyl; substituted alkyl; halo; heterocycloalkyl; heteroaryl; phenyl; substituted phenyl; naphthyl and substituted naphthyl;

B₁ is hydrogen;

10

B₂ is hydrogen; or B₁ and B₂ are methylene and joined together to form a five or six membered ring;

Y is methylene or carbonyl;

15

Z is selected from the group consisting of aryl; substituted aryl; N-sulfonamido; N-(aryl)sulfonamido; substituted N-(aryl)sulfonamido; arylamido; substituted arylamido; arylureido; substituted arylureido; arylacetamido; substituted arylacetamido; (aryloxy)carbonylamino; substituted (aryloxy)carbonylamino; 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl; substituted 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl; 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl; and substituted 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

20

L is C₁₋₆alkylene; C₂₋₁₀ alkenylene; C₂₋₁₀ alkynylene; C₃₋₇cycloalkylene;

25

C₃₋₇cycloalkylC₁₋₄alkylene; arylC₁₋₄ alkylene; α -aminoC₄₋₇alkylene; (N-methylene)piperidin-4-yl; substituted (N-methylene)piperidin-4-yl; (N-methylene)piperazin-4-yl; (N-methylene)pyrrolidin-3-yl; (N-methylene)-4-acetyl-piperidin-4-yl; and (N-methylene)piperidin-4,4-diyl;

30


n is 1-2;

m is 1-3;

p is 1-3; and







q is 1-3.

5 3. A compound of claim 1 selected from the group consisting of:









and

4. A compound of claim 1 selected from the group consisting of:




and

5. A compound of claim 1 selected from the group consisting of:




and

6. A compound of claim 1 selected from the group consisting of:








and

7. A compound of claim 1 selected from the group consisting of:




and

8. A compound of claim 1 selected from the group consisting of:









and

9. A compound of claim 1 selected from the group consisting of:









and

10. A compound of claim 1 selected from the group consisting of:




and

11. A compound of claim 1 selected from the group consisting of:



and

12. A compound of claim 1 selected from the group consisting of:



and

13. A compound of claim 1 selected from the group consisting of:

2-Amino-6-[(2-fluorophenylsulfonyl)amino]-N-[*cis*-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthenyl-(2*S*)-hexanamide bis-hydrochloride,

N-[5-amino-6-[[*cis*-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl-2-fluorobenzenesulfonamide tris-hydrochloride,

N-[5-amino-6-[[*cis*-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]amino]hexyl-2-fluorobenzenesulfonamide tris-hydrochloride,

(2*S*)-2-(Acetylamino)-6-[(2-fluorophenylsulfonyl)amino]-N-[*cis*-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthenyl]hexanamide bis-hydrochloride,

(2*S*)-2-(Acetylamino)-6-[(2-fluorophenylsulfonyl)amino]-N-[*cis*-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthenyl]hexanamide bis-hydrochloride,

3-[(Phenylsulfonyl)amino]-*N*-[*cis*-1,2,3,4-tetrahydro-6-fluoro-1-(3-pyridinylmethyl)-2-naphthalenyl]-1-pyrrolidineacetamide bis-trifluoroacetate,

4-(2,3-Dihydro-2-oxo-1*H*-benzimidazol-1-yl)-*N*-[*cis*-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-1-piperidineacetamide bis-hydrochloride,

4-(2,3-Dihydro-2-oxo-1*H*-benzimidazol-1-yl)-*N*-[*trans*-1,2,3,4-tetrahydro-6-methoxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-1-piperidineacetamide bis-hydrochloride,

4-Acetyl-4-phenyl-N-[*cis*-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-1-piperidineacetamide bis-hydrochloride,

5 4-Oxo-1-phenyl-N-[*cis*-1,2,3,4-tetrahydro-1-(3-pyridinylmethyl)-2-naphthalenyl]-1,3,8-triazaspiro[4.5]decane-8-acetamide bis-hydrochloride,

10 4-(2,3-Dihydro-2-oxo-1*H*-benzimidazol-1-yl)-N-[*cis*-1,2,3,4-tetrahydro-6-hydroxy-1-(3-pyridinylmethyl)-2-naphthalenyl]-1-piperidineacetamide bis-hydrochloride,

15 *trans*-N-[2-(4-fluorophenyl)-3-(3-pyridinyl)propyl]-4-[(2-fluorophenylsulfonyl)amino)methyl]-1-cyclohexanamide hydrochloride,

trans-N-[[[2-(4-fluorophenyl)-3-(3-pyridinyl)propyl]amino)methyl]-4-cyclohexyl)methyl] 2-fluorobenzenesulfonamide bis-hydrochloride and

20 N-[2-(4-fluorophenyl)-3-(3-pyridinyl)propyl]-4-[(2-fluorophenylsulfonyl)amino]-1-piperidineacetamide bis-trifluoroacetate.

14. A method of treating disorders and diseases associated with NPY receptor subtype 5 comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1.

15. A pharmaceutical composition for the treatment of diseases or disorders associated with the NPY Y5 receptor subtype comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

16. A pharmaceutical composition according to claim 15 for the treatment of disorders or disease states caused by eating disorders, obesity, bulimia

nervosa, diabetes, memory loss, epileptic seizures, migraine, sleep disturbances, pain, sexual/reproductive disorders, depression and anxiety.